Exciting update for North America customers

We are delighted to announce the launch of a brand-new branch office dedicated to serving the needs of RGCC Network doctors in North America.

Find out more
Download our app Order a test

Helping you to make informed decisions and formulate effective treatment plans

More about RGCC

Information for patients

We work with cancer patients to provide a range of personalised tests so you can choose the best treatment.

More patient information

Cancer tests

New methods and reliable tests to help deliver personalised treatment


RGCC CAMBISeq® is an innovative test that uses next-generation sequencing analysis on both DNA and RNA to provide clinicians with a crucial insight into cancer.  The CAMBISeq® – or cancer analysis, mutational burden and instability sequencing – test is used to identify variants in 500 genes that our scientists use as biomarkers to assess their […]

View test

Array comparative genomic hybridisation (aCGH) RGCC

The array comparative genomic hybridisation (aCGH) RGCC test is used to identify chromosomal abnormalities in a patient that could lead to cancer. During the test, scientists use a technique called array comparative genomic hybridisation to spot abnormalities in a genome. This insight enables them to assess the likely risk of cancer developing and the potential […]

View test


Immune-Frame is used to assess the condition of a patient’s immune system. Scientists use the test to identify specific cellular markers that are responsible for switching a patient’s immune system on and off. The results of Immune-Frame can be used to analyse the status of a patient’s immune system, and to provide ongoing information about […]

View test

Metastat RGCC

Metastat RGCC is an advanced test to detect specific blood-borne markers that can accurately determine whether a secondary cancerous tumour is likely to develop and its potential location. During the test, we analyse a sample of a patient’s blood in our state-of-the-art laboratory to analyse, identify and measure circulating tumour cells (CTCs). Metastat RGCC is […]

View test


ChemoSNiP is an innovative test that uses an advanced scientific technique called pharmacogenomics to analyse how a patient’s body will respond to a specific drug. ChemoSNiP analyses a blood sample to identify for single nucleotide polymorphisms – variations in our DNA sequence that can affect if we develop cancer or if we respond to treatments […]

View test

Onconomics Extracts

Onconomics Extracts is a unique and highly detailed test that provides information on how effective natural substances and plants extracts are at attacking circulating cancer cells (CTCs). Onconomics Extracts uses three unique and scientifically-proven methods to assess how effective natural treatments are at tackling cancer. The results provide a comprehensive and highly personalised analysis of […]

View test

Onconomics Plus RGCC

Onconomics Plus RGCC provides information about the effect of specific anti-cancer drugs, targeted therapies and natural treatments on the cancer cells in an individual patient. During the test, a sample of blood or tissue is analysed to test how effective specific therapies and treatments are at suppressing cancer. Together, the results of the extensive tests […]

View test

Onconomics RGCC

Onconomics RGCC provides highly detailed and accurate information about how effective specific anti-cancer drugs and targeted therapies are in treating cancer. The test combines a molecular and a cellular approach by incorporating two procedures: epigenetic analysis and viability assays. A sample of blood or tissue is analysed to test how effective specific therapies and treatments […]

View test

Oncotrail RGCC

Oncotrail RGCC provides crucial information on the presence of circulating tumour cells (CTCs) and their concentration in patients who have a confirmed diagnosis of specific forms of cancer, including breast, colon and prostate cancer. During the test, a sample of blood is analysed to identify the presence and concentration of CTC and their immunophenotype. Oncotrail […]

View test

Oncotrace RGCC

Oncotrace RGCC is used to identify a primary tumour in a patient and to provide guidance about disease progression and future prognosis. During the test, a sample of blood is analysed to identify the presence and concentration of circulating tumour cells (CTCs) and their concentration. This test provides information about the presence of CTCs, their […]

View test

Oncocount RGCC

Oncocount RGCC detects the presence of circulating tumour cells (CTCs) and their concentration in the blood. CTCs are a powerful biomarker, and their presence in the blood can act as an early warning sign that cancer is returning. The test is designed as a follow-up test for patients who have cancer and are worried about […]

View test
See all RGCC tests

Use our ‘smart filter’ to identify which test is best for your patients

Find out more

News & events

Find out more about our latest research, trials and education days

RGCC scientists develop novel new approach to inhibiting SARS-COV-2 replication

RGCC researchers have developed a new approach to tackling COVID-19 (SARS-CoV-2) that could form the basis of a new treatment option. Laboratory tests have established that the new treatments were effective at inhibiting the spread of the disease. The next stage will see them progress to develop a drug delivery system, a further step before […]

Read more

New cancer vaccine effective in 75% of tumours

A new cancer vaccine is 75% effective at eliminating cancerous tumours in mice, say scientists at the University of Konstanz. The combination treatment includes a powerful immunostimulant and a targeted immunotherapy called a cancer checkpoint inhibitor in one dose. Described by the team as a “potent cancer vaccine”, the combination therapy is already being tested […]

Read more

New blood test can diagnose cancer without tumour sample

US scientists have developed the world’s first ‘tumour-uninformed’ test that can detect cancer DNA circulating in the blood of cancer patients following treatment. The liquid biopsy test enables clinicians to test for cancer without needing a sample of tumour tissue. It’s an exciting development and adds yet more evidence to the potential for liquid biopsies […]

Read more

New Genistein capsule offers improved cancer-killing properties

RGCC scientists have developed a new anti-cancer dietary supplement that’s 34% more effective than the leading brand. Led by RGCC’s Dr Ioannis Papasotiriou, the new product offers yet more evidence of the potential for dietary supplements in the battle against cancer. It also demonstrates RGCC’s cutting-edge research and discovery capabilities. Genistein is a naturally occurring […]

Read more

Personalised cancer vaccine 45% effective at targeting tumours

Researchers have developed an effective vaccine that re-engineers cells from a patient’s tumour to target and destroy cancer cells. The results, published in the peer-reviewed Journal of Clinical Oncology, show that 45% of patients treated with an autologous cell vaccine, created from their own cancer cells, had a confirmed anti-tumour response. The findings provide more […]

Read more

Global Presence

RGCC operates in 23 countries across the world, with bases in all five continents.

Find out more